KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conference

        Print
| Source: KYTHERA Biopharmaceuticals, Inc.

CALABASAS, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Event: 32nd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2014
Time: 8:30 a.m. PT

A live webcast will be available under the Investors section of the Company's website at www.kytherabiopharma.com. The presentation will be archived on the website and will be available for at least 14 days.

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is currently in late stage clinical trials for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring.

Investor Contact:
Heather Rowe
Associate Director, Investor Relations
Tel: (818) 587- 4559